Evidence map›Paper›PMID 31319341›Full record

ArticleJournal of affective disorders2019

Brain serotonin transporter binding, plasma arachidonic acid and depression severity: A positron emission tomography study of major depression.

Manesh Gopaldas, Francesca Zanderigo, Serena Zhan, R Todd Ogden, Jeffrey M Miller, Harry Rubin-Falcone, Thomas B Cooper, Maria A Oquendo, Gregory Sullivan, J John Mann and 1 more

Abstract read
In one paragraph

Article in Journal of affective disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Emphasizing the Crosstalk Between Inflammatory and Neural Signaling in Post-traumatic Stress Disorder (PTSD).Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Manesh GopaldasDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States; Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, United States.
Francesca ZanderigoDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States.
Serena ZhanDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States.
R Todd OgdenDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States; Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States.
Jeffrey M MillerDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States.
Harry Rubin-FalconeDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States.
Thomas B CooperDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, United States.
Maria A OquendoPsychiatry Department, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Gregory SullivanTonix Pharmaceuticals Holding Corp, New York, NY, United States.
J John MannDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States; Department of Radiology, Columbia University, New York, NY, United States.
M Elizabeth SubletteDepartment of Psychiatry, Columbia University, New York, NY, United States; Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, United States. Electronic address: elizabeth.sublette@nyspi.columbia.edu.
New York Psychoanalytic Society and Institute · USColumbia University · USNathan Kline Institute for Psychiatric Research · USTonix Pharmaceuticals (United States)University of Pennsylvania · US

Funding

THE NEUROBIOLOGY OF SUICIDAL BEHAVIORP50MH062185 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MANN, JOSEPH JOHN · 2000 to 2009
$21.7M
Neurobiology of Depression and AntidepressantsR01MH040695 · NIMH · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI MANN, JOSEPH JOHN · 1986 to 2014
$7.1M
NIMH NIH HHS P50 MH062185NIMH NIH HHS R01 MH040695
6 · The paper itself

Abstract

backgroundSerotonin transporter (5-HTT) binding and polyunsaturated fatty acids (PUFAs) are implicated in major depressive disorder (MDD). Links between the two systems in animal models have not been investigated in humans.

methodsUsing positron emission tomography (PET) and [

resultsAA predicted both 5-HTT BP LIMITATIONS: Given the small sample and multiple comparisons, results require replication.

conclusionsOur findings suggest that AA status may impact depression pathophysiology through effects on serotonin transport. Future studies should examine whether these relationships explain therapeutic effects of PUFAs in the treatment of MDD.

Indexed as

AdultAnimalsArachidonic AcidBrainDepressionDocosahexaenoic AcidsEicosapentaenoic AcidFemaleHumansLinear ModelsMajor Depressive DisorderMaleMiddle AgedPositron-Emission TomographySerotonin Plasma Membrane Transport ProteinsArachidonic AcidDocosahexaenoic AcidsEicosapentaenoic Acideicosapentaenoic acid ethyl esterSerotonin Plasma Membrane Transport Proteins[(11)C]DASBArachidonic acidDepressionPETPolyunsaturated fatty acidsSerotonin transporter

Identifiers

PMID31319341
PMCPMC6886679
OpenAlexW2953640613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.